BullFrog has exclusive, worldwide license agreements with major U.S. biomedical institutions to advance promising drug candidates.

Our industry-leading bfLEAP™ technology platform has the potential to streamline and de-risk multiple steps of the drug development process.

Demonstrated Success Advancing In-Licensed Assets

Phase I
Phase II
Phase III

Candidate: Repurposed small molecule for cancer therapy

Our most advanced drug asset is a repurposed small molecule therapeutic that has been formulated to improve bioavailability and increase the likelihood of demonstrating efficacy. Preclinical animal data indicate the potential of this drug to treat a variety of cancers, and the company will target glioblastoma as an initial indication. Subsequent programs are anticipated for other undisclosed indications. 


Candidate: Novel mebendazole prodrug for cancer therapy

BF-223 is a novel mebendazole prodrug that has shown in animal studies that it possesses significantly improved solubility and oral bioavailability compared to mebendazole, thereby enhancing its potential utility as a therapeutic agent. The US patent for this invention was recently issued, providing strong protection for BF-223, and BullFrog AI is considering clinical programs in glioblastoma and additional oncology indications. 


Our second candidate, which is in preclinical development, is a novel nucleic acid therapeutic that shows potential in the treatment of numerous metabolic indications including obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma.  

Liver Cancer (HCC)
Morbid Obesity

Candidate: Oncolytic virus

The third program in BullFrog AI’s pipeline is a co-development project with the J. Craig Venter Institute (JCVI) to design, engineer, and validate a novel, precision-engineered oncolytic virus specifically targeting colorectal cancer. 

Colorectal Cancer